Cardiovascular and pulmonary adverse events in patients treated with BCR‐ABL inhibitors: Data from the FDA Adverse Event Reporting System

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|4|E66-E72

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.4, 2015-04, pp. : E66-E72

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Performance of Pharmacovigilance Signal‐Detection Algorithms for the FDA Adverse Event Reporting System

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 6, 2013-06 ,pp. : 539-546

John Wiley & Sons Inc

Access to resources Recommend Favorite

Paraesthesia after Local Anaesthetics: An Analysis of Reports to the FDA Adverse Event Reporting System

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 1, 2015-07 ,pp. : 52-56

John Wiley & Sons Inc

Access to resources Recommend Favorite

Developing a Comprehensive Electronic Adverse Event Reporting System in an Academic Health Center

By Kivlahan Coleen   Sangster William   Nelson Kathryn   Buddenbaum Jennifer   Lobenstein Kenneth  

Joint Commission Journal on Quality and Patient Safety, Vol. 28, Iss. 11, 2002-11 ,pp. : 583-594

Joint Commission Resources

Access to resources Recommend Favorite

Association rule mining in the US Vaccine Adverse Event Reporting System (VAERS)

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 24, Iss. 9, 2015-09 ,pp. : 922-933

John Wiley & Sons Inc

Access to resources Recommend Favorite

SOP 08: Reporting of Adverse Events

By  

Oncology Research and Treatment, Vol. 26, Iss. 6, 2004-11 ,pp. : 41-42

Karger

Access to resources Recommend Favorite